How Palpable, Nonpalpable Cancers Differ

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

WASHINGTON-Palpable and nonpalpable breast cancers differ in a variety of inherent characteristics, reported Kristin Skinner, MD, of the University of Southern California Norris Comprehensive Cancer Center, Los Angeles. She presented her study results at the 54th Annual Cancer Symposium of the Society of Surgical Oncology.

WASHINGTON—Palpable and nonpalpable breast cancers differ in a variety of inherent characteristics, reported Kristin Skinner, MD, of the University of Southern California Norris Comprehensive Cancer Center, Los Angeles. She presented her study results at the 54th Annual Cancer Symposium of the Society of Surgical Oncology.

Nodal involvement had been known to occur twice as often in palpable as in nonpalpable breast cancers, Dr. Skinner commented. To investigate whether inherent differences separate these tumors from nonpalpable cancers, the researchers reviewed a prospective database of T1 breast cancers dating back to 1981.

Of the 1,263 cancers in the database, 859 (68%) were palpable and 404 (32%) were not. The cancers did not differ in distribution between ductal and lobular types. The database contained no data on the size of the patients’ breasts. Size of tumors was determined by 3-dimensional reconstruction of pathologic samples.

The investigators compared the two types of cancer for a variety of characteristics, including tumor size, receptor status, HER-2/neu status, nodal status, multifocality, multicentricity, presence of lymphovascular invasion and extensive intraductal component, mitotic and nuclear grades, ploidy, and S-phase.

The examination of the pathologic characteristics showed that the palpable cancers had larger size, less multicentricity, less multifocality, more nuclear abnormalities, and more metastatic potential, she said.

At 8 years, the breast-cancer-specific survival of patients with palpable tumors, adjusted for stage, was significantly worse than that of patients with nonpalpable tumors, 87% vs 95%, respectively.

Most breast cancer diagnoses still result from palpation, despite improvements in mammography, Dr. Skinner noted.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content